Keyword: HPAPIs

Strategy & Management

Expansions in High-Potency API Manufacturing

14.09.2020 -

DCAT Value Chain Insights rounds up recent expansion activity for highly potent drug substances and drug products.

Chemistry & Life Sciences

Understanding the Requirements of Safe HPAPI Manufacturing

11.09.2020 -

The pharmaceutical industry is increasingly focused on the development of specialized drug products with new treatment modalities, including previously undruggable...

Chemistry & Life Sciences

The Rise of HPAPI Molecules

10.09.2020 -

For biopharma leaders it is more critical than ever to secure the capabilities to contain, handle, develop and manufacture highly potent APIs.

News

Francesca Scarpitta Joins Cerbios as Director of HPAI Manufacturing Units

24.01.2019 -

Cerbios has appointed Francesca Scarpitta as director of the company’s high potency active ingredients (HPAIs) production units.

News

Cerbios Expands HPAI Manufacturing Capacity

24.01.2019 -

Lugano, Switzerland-based chemical and biological API manufacturer Cerbios announced that its board of directors has approved the installation of a new production line in...

News

Lonza and Clovis Open New Monoplant for Ovarian Cancer Drug

04.10.2018 - Lonza and Clovis Oncology have opened a new, dedicated production train for Rubraca (rucaparib), at Lonza’s Visp site in Switzerland. Rubraca is Clovis’ US- and EU-approved drug...

Strategy & Management

Science that Enables Solutions for Clean Air, Improved Health and Sustainable Use of Resources

27.09.2017 - 2017 marks the 200th anniversary of UK specialty chemical and technology group Johnson Matthey which – back in 1817 – began as assayers, testing the purity of precious metals. In...

Markets & Companies

Meeting Customers’ Changing Needs

24.05.2017 - Johnson Matthey, which was founded in London in 1817, is celebrating its 200th anniversary this year. Through the constant application of new ideas and new processes, the company...